RxDoctor Payments Data

Jose Mathew, MD

Cardiovascular Disease · Leesville, LANPI 1699744987

Payments from drug & device makers

$819in general payments, 2019–2025

Across 30 payments — averaging $27.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stimwave Technologies Incorporated$180
  • Johnson & Johnson$152
  • Abbott$99
  • Vertos Medical, Inc.$95
  • Novartis$47
  • Abiomed$45
  • plus $200 from 9 others

What the payments were for

  • Food & beverage$819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$819 in reported general payments places this provider in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$597,588
Medicare patients
954
Services billed
15,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$279,708
JardianceEmpagliflozin138$151,161
OzempicSemaglutide69$103,950
XareltoRivaroxaban88$89,570
Repatha SureclickEvolocumab69$70,107
TrulicityDulaglutide30$67,185
FarxigaDapagliflozin Propanediol70$62,740
EntrestoSacubitril/Valsartan47$61,781
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$47,163
MultaqDronedarone Hcl30$41,547
JanumetSitagliptin Phos/Metformin Hcl33$37,877
JanuviaSitagliptin Phosphate53$35,335
Praluent PenAlirocumab25$24,765
MounjaroTirzepatide23$23,527
VascepaIcosapent Ethyl38$21,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$103,95069 claims
Johnson & JohnsonXarelto$152$89,57088 claims
NovartisEntresto$47$61,78147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Leesville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →